Fig. 5

Epigenetic modifications status in the TLR4 promoter in CAD patients and LDL-treated CD14⁺ monocytes. a The DNA methylation levels of 4 CG pairs (from − 1086 bp to − 421 bp upstream of the TLR4 TSS) was detected by bisulfite sequencing in CAD CD14⁺ monocytes. b DNA methylation levels of 4 CG pairs (from − 1086 bp to − 421 bp upstream of the TLR4 TSS) was detected by bisulfite sequencing. The percentage change of methylation level in each CG pair was shown between LDL-treatment and control group. c The mean DNA methylation level of all the 4 CG pairs (from − 1086 bp to − 421 bp upstream of the TLR4 TSS) was calculated in CAD CD14⁺ monocytes. d The mean DNA methylation of all the 4 CG pairs (from − 1086 bp to − 421 bp upstream of the TLR4 TSS) was calculated. The percentage change of mean methylation was shown between LDL treatment and control group. e The H3 acetylation level in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in CAD CD14⁺ monocytes. f The fold change of H3 acetylation in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in LDL-treated CD14⁺ monocytes. g The H4 acetylation level in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in CAD CD14⁺ monocytes. h The fold change of H4 acetylation in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in LDL-treated CD14⁺ monocytes. i The H3K9 trimethylation level in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in CAD CD14⁺ monocytes. j The fold change of H3K9 trimethylation in TLR4 promoter with RFX1 binding region were detected by ChIP-qPCR in LDL-treated CD14⁺ monocytes. The fold changes were shown between LDL treatment and control group. All values are the average of at least three biological replicates, and the data shown are the means ± SDs. *P < 0.05; **P < 0.01 relative to control